Inferences on a life distribution by sampling from the ages or the ages at death.
- Published in:
- Lifetime Data Analysis, 2006, v. 12, n. 3, p. 305, doi. 10.1007/s10985-006-9010-4
- By:
- Publication type:
- Article
Works by Rothmann, Mark D.
Results: 7
1
2
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia.
- Published in:
- Oncologist, 2014, v. 19, n. 1, p. 94, doi. 10.1634/theoncologist.2013-0077
- By:
- Publication type:
- Article
3
U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Oncologist, 2011, v. 16, n. 1, p. 97, doi. 10.1634/theoncologist.2010-0306
- By:
- Publication type:
- Article
4
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events.
- Published in:
- Statistics in Medicine, 2025, v. 44, n. 10-12, p. 1, doi. 10.1002/sim.70104
- By:
- Publication type:
- Article
5
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.
- Published in:
- Clinical Trials, 2023, v. 20, n. 4, p. 341, doi. 10.1177/17407745231169692
- By:
- Publication type:
- Article
6
Some essential considerations in the design and conduct of non-inferiority trials.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 432, doi. 10.1177/1740774511410994
- By:
- Publication type:
- Article
7
Statement on P-values.
- Published in:
- 2021
- By:
- Publication type:
- Letter